Magnetic Flux Emergence, Activity, Eruptions and Magnetic Clouds: Following Magnetic Field from the Sun to the Heliosphere

We present an overview of how the principal physical properties of magnetic flux which emerges from the toroidal fields in the tachocline through the turbulent convection zone to the solar surface are linked to solar activity events, emphasizing the effects of magnetic field evolution and interaction with other magnetic structures on the latter. We compare the results of different approaches using various magnetic observables to evaluate the probability of flare and coronal mass ejection (CME) activity and forecast eruptive activity on the short term (i.e. days). Then, after a brief overview of the observed properties of CMEs and their theoretical models, we discuss the ejecta properties and describe some typical magnetic and composition characteristics of magnetic clouds (MCs) and interplanetary CMEs (ICMEs). We review some individual examples to clarify the link between eruptions from the Sun and the properties of the resulting ejecta. The importance of a synthetic approach to solar and interplanetary magnetic fields and activity is emphasized. © 2008 Springer Science+Business Media B.V

Catalogue des outils d'aide a la decision dans le domaine de l'energie pour les collectivites locales

Available from INIST (FR), Document Supply Service, under shelf-number : RP 400 (2202) / INIST-CNRS - Institut de l'Information Scientifique et TechniqueSIGLEAgence de l'Environnement et de la Maitrise de l'Energie (ADEME), 75 - Paris (France)FRFranc

Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry

Aim: The SAMe-TT2R2 score helps identify patients with atrial fibrillation (AF) likely to have poor anticoagulation control during anticoagulation with vitamin K antagonists (VKA) and those with scores >2 might be better managed with a target-specific oral anticoagulant (NOAC). We hypothesized that in clinical practice, VKAs may be prescribed less frequently to patients with AF and SAMe-TT2R2 scores >2 than to patients with lower scores. Methods and results: We analyzed the Phase III dataset of the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), a large, global, prospective global registry of patients with newly diagnosed AF and ≥1 stroke risk factor. We compared baseline clinical characteristics and antithrombotic prescriptions to determine the probability of the VKA prescription among anticoagulated patients with the baseline SAMe-TT2R2 score >2 and ≤ 2. Among 17,465 anticoagulated patients with AF, 4,828 (27.6%) patients were prescribed VKA and 12,637 (72.4%) patients an NOAC: 11,884 (68.0%) patients had SAMe-TT2R2 scores 0-2 and 5,581 (32.0%) patients had scores >2. The proportion of patients prescribed VKA was 28.0% among patients with SAMe-TT2R2 scores >2 and 27.5% in those with scores ≤2. Conclusions: The lack of a clear association between the SAMe-TT2R2 score and anticoagulant selection may be attributed to the relative efficacy and safety profiles between NOACs and VKAs as well as to the absence of trial evidence that an SAMe-TT2R2-guided strategy for the selection of the type of anticoagulation in NVAF patients has an impact on clinical outcomes of efficacy and safety. The latter hypothesis is currently being tested in a randomized controlled trial. Clinical trial registration: URL: https://www.clinicaltrials.gov//Unique identifier: NCT01937377, NCT01468701, and NCT01671007. © 2020 Hellenic Society of Cardiolog